Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

314.85 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3
Open 314.85
Bid (Size) 310.32 (1)
Ask (Size) 315.41 (1)
Prev. Close 314.85
Today's Range 314.85 - 314.85
52wk Range 218.44 - 329.72
Shares Outstanding N/A
Dividend Yield 2.71%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day." 
Via Benzinga
Topics ETFs
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $5,700 Today
Via Benzinga

Performance

YTD
+5.87%
+5.87%
1 Month
+15.79%
+15.79%
3 Month
+11.05%
+11.05%
6 Month
+19.80%
+19.80%
1 Year
+37.83%
+37.83%

More News

Read More
7 Reliable Blue-Chip Stocks That Cannot Miss
Via InvestorPlace
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Via Benzinga
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Via InvestorPlace
Amgen Unusual Options Activity
Via Benzinga
Market Whales and Their Recent Bets on AMGN Options
Via Benzinga
How Is The Market Feeling About Amgen?
Via Benzinga
Dow Jones Industrial Average Closes Above 40,000 In Quiet Friday Climb
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Via The Motley Fool
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
Via Benzinga
Topics Cannabis
Exposures Cannabis
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
Via InvestorPlace
FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients
Via Benzinga
Exposures Product Safety
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Via The Motley Fool
S&P 500, Nasdaq 100, Dow Jones Shatter Record Highs In Unstoppable Bull Market Rally
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
The 3 Best Dow Stocks to Buy in May 2024
Via InvestorPlace
Topics Stocks
Exposures US Equities
Amgen Is Working On a Wegovy Competitor -- What It Means for Investors
Via The Motley Fool
5 Stocks Driving Dow's Market-Beating Performance
Via Talk Markets
Topics Stocks
Exposures US Equities
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
Via InvestorPlace
Trade Desk To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Wall Street Stares At Weaker Open On Rate Anxiety, Hopes For Better Earnings: Analyst Pencils Key S&P 500 Support Level
Via Benzinga
Topics Stocks
Exposures US Equities
Sector Superstars: 3 Stocks Generating the Most Buzz on Wall Street
Via InvestorPlace
Dow Jones Industrial Average Pushes Higher On Wednesday Despite Tepid Risk Appetite
Via Talk Markets
Topics Stocks
Exposures US Equities
3 Tried and True Dividend Stocks to Buy for Your Portfolio
Via InvestorPlace
The Option Market Shows The Way Through This Low-Volume, Fed-Driven Melt-Up
Via Talk Markets
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.